Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy

N Engl J Med. 2016 Jul 21;375(3):296-7. doi: 10.1056/NEJMc1515584.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Action Potentials
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Female
  • Humans
  • Melanoma / drug therapy
  • Middle Aged
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / physiopathology
  • Polyradiculoneuropathy / chemically induced*
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / chemically induced

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • pembrolizumab